雷珠单抗联合玻璃体切割术治疗糖尿病视网膜病变合并新生血管性青光眼

发布时间：2018-11-28 15:39

【摘要】：目的观察雷珠单抗联合玻璃体切割术治疗糖尿病视网膜病变合并新生血管性青光眼的临床效果。方法回顾性分析糖尿病视网膜病变合并新生血管性青光眼并行雷珠单抗联合玻璃体切割术的16例(16眼)患者的临床资料。术后随访6个月,对比观察手术前后眼压、最佳矫正视力、虹膜新生血管、房角开闭情况等,并记录并发症情况。结果术前患眼眼压为(42.54±16.52)mmH g(1 kP a=7.5 mmH g)。玻璃体内注射雷珠单抗后1 d眼压为(38.78±11.38)mmH g,与术前相比差异无统计学意义(P0.05);玻璃体切割术后1周眼压(45.30±12.20)mmH g,与术前相比差异无统计学意义(P0.05);术后1个月、3个月、6个月眼压分别为(27.56±19.38)mmH g、(20.49±18.66)mmH g、(19.79±16.53)mmH g,与术前相比差异均有统计学意义(均为P0.05)。随访结束时,10眼(62.5%)虹膜新生血管完全消退,6眼(37.5%)虹膜新生血管明显减少。结论雷珠单抗联合玻璃体切割术治疗糖尿病视网膜病变合并新生血管性青光眼,可有效降低眼压,轻度提高视力,术后并发症少。
[Abstract]:Objective to observe the clinical effect of Leizhu McAb combined with vitrectomy in the treatment of diabetic retinopathy with neovascular glaucoma. Methods the clinical data of 16 patients (16 eyes) with diabetic retinopathy complicated with neovascular glaucoma and vitrectomy were retrospectively analyzed. The intraocular pressure, best corrected visual acuity, iris neovascularization, atrial angle opening and closing were observed and the complications were recorded. Results preoperative IOP was (42.54 卤16.52) mmH g (1 kP a 7.5 mmH g). The intravitreal intraocular pressure (IOP) was (38.78 卤11.38) mmH g,) after injection of Lei Zhu McAb (P0.05). Intraocular pressure (IOP) 1 week after vitrectomy (45.30 卤12.20) mmH g,) was not significantly different from that before vitrectomy (P0.05). The intraocular pressure (IOP) was (27.56 卤19.38) mmH g, (20.49 卤18.66) mmH g, (19.79 卤16.53) mmH g,) at 1 month, 3 months and 6 months after operation respectively, which was significantly different from that before operation (P0.05). Iris neovascularization disappeared completely in 10 eyes (62.5%) and iris neovascularization decreased in 6 eyes (37.5%) at the end of follow-up. Conclusion Threzumab combined with vitrectomy in the treatment of diabetic retinopathy with neovascular glaucoma can effectively reduce intraocular pressure, slightly improve visual acuity, and have less postoperative complications.
【作者单位】：武汉大学人民医院眼科中心;
【分类号】：R587.2;R779.6

【相似文献】